Last Updated : April 18, 2024
Details
Generic Name:
cariprazine
Project Status:
Active
Therapeutic Area:
Schizophrenia
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Vraylar
Project Line:
Reimbursement Review
Project Number:
SR0827-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Indications:
For the treatment of schizophrenia in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | November 08, 2023 |
|---|---|
| Call for patient/clinician input closed | January 08, 2024 |
| Clarification: - Patient input submission received from Schizophrenia Society of Canada | |
| Submission received | December 20, 2023 |
| Submission accepted | January 11, 2024 |
| Review initiated | January 12, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | April 08, 2024 |
| Deadline for sponsors comments | April 17, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | May 09, 2024 |
| Expert committee meeting (initial) | May 22, 2024 |
| Draft recommendation issued to sponsor | June 03, 2024 To June 05, 2024 |
| Draft recommendation posted for stakeholder feedback | June 13, 2024 |
| End of feedback period | June 27, 2024 |
Last Updated : April 18, 2024